Analysts Defend Merck Amid Investor Concerns Over Weak Guidance
Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of foreign exchange, ...
The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck
Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.
Should You Pick MRK Stock At $90?
Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.
FiercePharma8h
With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
Merck’s Gardasil Halt Shows Blockbuster Shots’ Dilemma in China
Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the ...
Merck & Co., Inc. (NYSE:MRK) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...
Merck Is Suffering From a Classic Pharma Problem
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
BMJ12h
Robert F Kennedy is likely to be confirmed as head of US health department after contentious committee vote
The Senate Finance Committee voted to approve Robert F Kennedy Jr as head of the US Department of Health and Human Services by a vote of 14-13 on 4 February. The full Senate will vote on his ...
BioPharma Dive18h
Merck shares tumble as company pauses Gardasil shipments to China
Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.